OFF-TARGET EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: ADDITIONAL THERAPEUTIC BENEFITS
https://doi.org/10.15829/1728-8800-2013-6-21-23
Abstract
The paper is focused on additional, or off-target, effects of angiotensinconverting enzyme inhibitors (ACEI), zofenopril in particular. This is a new area in the pharmacological research, which is also relevant to antihypertensive agents. The authors present the data on potential interaction between ACEI and acetylsalicylic acid, as well as the results of international multi-centre studies.
About the Authors
O. Yu. Shaidyuk
N.I. Pirogov Russian National Medical Research University, Moscow
Russian Federation
Russian Federation
E. O. Taratukhin
N.I. Pirogov Russian National Medical Research University, Moscow
Russian Federation
Russian Federation
tel.: +79166372978
References
1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESHESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013; doi:10.1093/eurheart/eht151.
2. Streicher JM, Wang Y. The role of COX-2 in heart pathology. Cardiovasc Hematol Agents Med Chem. 2008; 6 (1): 69–79.
3. Głuszek J, Tykarski A, Jankowska K. Is it recommended simultaneous use of acetylsalicylic acid and angiotensin converting enzyme inhibitors? Pol Arch Med Wewn. 2005; 114 (3): 906–12.
4. Borghi C, Ambrosioni E, Novo S, et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol. 2012;35 (7): 416–23.
5. Borghi C, Ambrosioni E, Omboni S, et al. Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. Clinicoecon Outcomes Res. 2013 Jul 8; 5: 317–25.
6. Borghi C, Cosentino ER, Rinaldi ER, Cicero AF. Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am J Cardiol. 2013;112 (1):90–3.
7. Borghi C, Bacchelli S, Degli Esposti D. Long-term clinical experience with zofenopril. Expert Rev Cardiovasc Ther. 2012; 10 (8): 973–82.
8. Bozcali E, Dedeoglu DB, Karpuz V, et al. Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity. Acta Cardiol. 2012; 67 (1): 87–96.
9. Omboni S, Borghi C. Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag. 2011;7:459–71.
10. Cacciatore F, Bruzzese G, Vitale DF, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011; 67 (9):877–83.
11. Uzar E, Acar A, Evliyaoğlu O, et al. The antioxidant and anti-apoptotic effects of nebivolol and zofenopril in a model of cerebral ischemia/ reperfusion in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 36 (1):22–8.
12. Borghi C, Cicero AF, Bacchelli S, et al. Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam Clin Pharmacol. 2009; 23 (5):641–8.
13. Bălan H, Popescu E, Angelescu G. Comparing different treatment schedules of Zomen (zofenopril). Rom J Intern Med. 2011;49 (1):75–84.
14. Carnicelli V, Frascarelli S, Zucchi R. Effect of acute and chronic zofenopril administration on cardiac gene expression. Mol Cell Biochem. 2011; 352 (1–2):301–7.
15. Napoli C, Bruzzese G, Ignaro L, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxideoxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Cardiovascular Therapy and Prevention. 2012; 11: 93–101. Russian (Наполи К, Бруцессе Дж, Игнарро Л. Дж. и др. Долгосрочная терапия сульфгидрильным ингибитором ангиотензин-превращающего фермента замедляет утолщение комплекса интима-медиа сонных артерий, улучшает показатели обмена оксида азота и окислительного стресса у пациентов с впервые диагностированной первичной мягкой артериальной гипертонией. Кардиоваскулярная терапия и профилактика. 2012; 11:93– 101).
16. Morozova TE, Andrushchitsina TB. Possible antihypertensive interventions in comorbid coronary heart disease and systemic hypertension. Russ J Cardiol. 2013; 4:88–94. Russian (Морозова Т.Е., Андрущицина Т.Б. Возможности комбинированной антигипертензивной терапии при сочетании артериальной гипертензии и ишемической болезни сердца. Российский кардиологический журнал. 2013; 4:88–94).
Review
For citations:
Shaidyuk O.Yu., Taratukhin E.O. OFF-TARGET EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: ADDITIONAL THERAPEUTIC BENEFITS. Cardiovascular Therapy and Prevention. 2013;12(6):21-23. (In Russ.) https://doi.org/10.15829/1728-8800-2013-6-21-23
Views:
534
Email this article 
